Thermo Fisher Scientific Inc. $TMO Shares Sold by Alecta Tjanstepension Omsesidigt

Key Points

• Alecta Tjanstepension Omsesidigt has reduced its stake in Thermo Fisher Scientific Inc. by 16.2%, holding 712,900 shares after selling 137,800 shares during the 2nd quarter.
• Thermo Fisher reported $5.36 earnings per share for the last quarter, exceeding analysts' expectations, with revenue rising 2.9% year-over-year.
• The company declared a quarterly dividend of $0.43 per share, with an annualized yield of 0.4%, to be paid on October 15th.

Alecta Tjanstepension Omsesidigt trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 16.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 712,900 shares of the medical research company's stock after selling 137,800 shares during the quarter. Thermo Fisher Scientific makes up about 1.4% of Alecta Tjanstepension Omsesidigt's holdings, making the stock its 27th biggest position. Alecta Tjanstepension Omsesidigt owned 0.19% of Thermo Fisher Scientific worth $288,938,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. CBIZ Investment Advisory Services LLC increased its stake in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after buying an additional 33 shares during the period. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $30,000. Anderson Financial Strategies LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $30,000. Finally, Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the 1st quarter valued at $31,000. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $1.08 on Friday, hitting $480.02. The company's stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $623.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. The firm has a fifty day moving average price of $472.01 and a 200-day moving average price of $450.02. The company has a market capitalization of $181.26 billion, a P/E ratio of 27.76, a price-to-earnings-growth ratio of 2.57 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Wall Street Analysts Forecast Growth

TMO has been the topic of several recent research reports. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $490.00 to $550.00 in a research note on Thursday, September 11th. Hsbc Global Res lowered shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price on the stock in a research report on Friday, July 11th. HSBC restated a "hold" rating and set a $510.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Royal Bank Of Canada set a $561.00 target price on shares of Thermo Fisher Scientific and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Seventeen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $592.24.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.